• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Eloxx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Jocelyn Aspa
    Jun. 20, 2019 08:54AM PST
    Pharmaceutical Investing

    Eloxx Pharmaceuticals (NASDAQ:ELOX) has announced the pricing of its public offering of common stock at US$9 per share for over 3.3 million shares totalling US$30 million. As quoted in the press release:  The offering is expected to close on or about June 24, 2019, subject to customary closing conditions. In addition, Eloxx has granted the underwriters …

    Eloxx Pharmaceuticals (NASDAQ:ELOX) has announced the pricing of its public offering of common stock at US$9 per share for over 3.3 million shares totalling US$30 million.

    As quoted in the press release:

     The offering is expected to close on or about June 24, 2019, subject to customary closing conditions. In addition, Eloxx has granted the underwriters a 30-day option to purchase up to 500,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. All shares in the offering are being sold by Eloxx.

    Eloxx anticipates using the net proceeds from the offering to fund the continued clinical development of ELX-02 in cystic fibrosis and cystinosis, to accelerate development of early-stage programs and for working capital and other general corporate purposes.

    Citigroup and Piper Jaffray & Co. are acting as joint book-running managers for the offering.

    Click here to read the full press release.

    eloxx pharmaceuticalspublic offeringpharmaceutical investingnasdaq:elox
    The Conversation (0)

    Go Deeper

    AI Powered

    Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    Medical pills branded with Canadian flag.

    Canadian Pharma Stocks: 5 Biggest Companies

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA

    Principal Technologies

    PTEC:CC
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×